The BMJ raises fresh concerns over ROCKET AF

As part of its ongoing investigation The BMJ has claimed the manufacturer of rivaroxaban (Xarelto, Janssen) withheld from regulators information about a faulty device used in the pivotal ROCKET AF trial that could have skewed data in favour of the drug. In its investigation published on Thursday the journal also claims that patients involved in the ...

Already a member?

Login to keep reading.

© 2021 the limbic